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In this study of antibodies to SARS-CoV-2 among health care workers in three counties in Kenya, we 





















Few studies have assessed the seroprevalence of antibodies against SARS-CoV-2 among 
Health Care Workers (HCWs) in Africa. We report findings from a survey among HCWs in 
three counties in Kenya.  
Methods   
We recruited 684 HCWs from Kilifi (rural), Busia (rural) and Nairobi (urban) counties. The 
serosurvey was conducted between 30th July 2020 and 4th December 2020. We tested for 
IgG antibodies to SARS-CoV-2 spike protein using ELISA. Assay sensitivity and specificity were 
93% (95% CI 88-96%) and 99% (95% CI 98-99.5%), respectively. We adjusted prevalence 
estimates using Bayesian modeling to account for assay performance. 
Results 
Crude overall seroprevalence was 19.7% (135/684). After adjustment for assay performance 
seroprevalence was 20.8% (95% CrI 17.5-24.4%). Seroprevalence varied significantly 
(p<0.001) by site: 43.8% (CrI 35.8-52.2%) in Nairobi, 12.6% (CrI 8.8-17.1%) in Busia and 
11.5% (CrI 7.2-17.6%) in Kilifi. In a multivariable model controlling for age, sex and site, 
professional cadre was not associated with differences in seroprevalence.  
Conclusion 
These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among 
HCWs in Kenya. There was significant variation in seroprevalence by region, but not by 
cadre.  



















Health care workers (HCWs) are critical in the acute-care response to epidemic waves of 
COVID-19, but they are also required to sustain normal health services beyond COVID-19. 
HCWs are considered to be at high risk of infection with SARS-CoV-21. It is unclear whether 
the seroprevalence of SARS-CoV-2 antibodies among HCWs is more closely associated with 
community or hospital-based transmission risk as indicated by professional cadre. In some 
hospitals, seroprevalence was higher among cadres in lower paid jobs with little patient 
contact (e.g. housekeepers, porters) suggesting the source of infection may be their 
crowded living conditions rather than occupational risk2. The true extent of infection in 
HCWs in Kenya has been difficult to determine, due to factors including (1) the fact that a 
large proportion of infections (>90%) are asymptomatic3, possibly because of the young 
population structure; and (2) because of challenges in PCR testing of nasal and 
oropharyngeal (NP/OP) swabs in Kenya4 and, indeed most low and middle-income countries 
(LMICs).  
Serological surveys can estimate cumulative incidence of SARS-CoV-2 infection in either key 
groups, such as HCWs, or the general population5. They can also assess the effectiveness of 
infection prevention and control measures, which is important in sub-Saharan Africa (sSA) 
where the availability of personal protective equipment and other preventive measures is 
constrained. To date HCW serosurveys in sSA have been limited to urban hospitals6-8; there 
are no surveys from rural hospitals, where resources are even more constrained. 
Serosurveys on different population groups or in different geographical regions can also 
inform vaccine prioritization policies. This is especially important in LMICs where only a 


















Because the presence of antibodies to SARS-CoV-2 appears to be strongly protective against 
repeat infection over a 6-month period10, 11, knowledge of past infection could be useful for 
avoiding unnecessary quarantines which would help preserve the limited numbers of 
personnel available to deal with the pandemic and other health needs in the region. 
We report initial findings from SARS-CoV-2 antibody testing from HCWs in three sites in 
Coastal, Central, and Western Kenya.  
 
METHODS 
Study sites and Participants 
Study sites (Figure S1) were selected after consultation with the individual county COVID-19 
Rapid Response Teams (RRTs). For Kilifi County, a predominantly rural area located on the 
Indian Ocean coast, we enrolled participants at Kilifi County Hospital, which is the main 
referral facility in the region. For Busia County, which is also predominantly rural and located 
in the western region of Kenya, we enrolled HCWs at Busia County Referral Hospital, the 
main referral facility in the area, and two other facilities in the county; Alupe Sub-County 
Hospital which has been designated as the isolation facility for COVID-19 patients in the 
county, and Kocholia Sub-County Hospital. In Nairobi County, the capital city of Kenya, we 
enrolled HCWs at the Kenyatta National Hospital (KNH), the main referral facility for the city 
as well as the country12.  
We used a variety of strategies to recruit a convenience sample of HCWs at each of the 
study sites, including word of mouth, advertising at hospital notice boards and messages 
sent via mobile phone. HCWs of all cadres were eligible to participate in the study. In Kilifi 
and Busia we aimed to recruit ≥ 50% (N=441) of the 882 HCWs working in the healthcare 

















sample. We used a slightly different strategy at KNH, where the primary aim of the study 
was to determine incidence and antibody kinetics among ~180 HCWs, comprising ~4% of the 
hospital’s estimated 5,000 HCWs 12l, who were likely (by self-report) to be available for a 
year-long longitudinal study. 
Ethics and Consents 
Serosurveillance was conducted as a public health activity requested by the Kenya Ministry 
of Health and ethical approval for collection and publication of these data was obtained 
from the Kenya Medical Research Institute Scientific and Ethics Review Unit 
(KEMRI/SERU/CGMR-C/203/4085). HCWs provided written and/or verbal informed consent 
for participation in the study. Results of the antibody testing were reported confidentially to 
each HCW together with information explaining the implications of the test results. 
Sample collection and processing 
The study took place between 30th July 2020 and 4th December 2020. Data collection was 
performed by members of staff from the participating hospitals, trained on the study 
procedures.  
 We collected 6ml of venous blood in sodium heparin tubes from each participant. Serum 
was obtained by centrifuging the samples at 450 x g for 5 minutes before storage at –80ºC. 
Samples were then transported in dry ice to the KEMRI-Wellcome Trust research 
laboratories in Kilifi for assays. 
A simple one-page questionnaire (provided in the appendix) was administered to the HCWs 



















ELISA for SARS-CoV-2 Spike Protein 
All samples were tested at the KWTRP laboratories in Kilifi for IgG to SARS-CoV-2 whole 
spike protein using an adaptation of the Krammer Enzyme Linked Immunosorbent Assay 
(ELISA)13. We assumed an assay sensitivity of 92.7% (95% CI 87.9-96.1%) and specificity of 
99.0% (95% CI 98.1-99.5) based on validation studies that we had previously conducted14. 
Results were expressed as the ratio of test OD to the OD of the plate negative control; 
samples with OD ratios greater than two were considered positive for SARS-CoV-2 IgG.  
Statistical methods 
Continuous variables were summarized as means and standard deviations if normally 
distributed and medians with interquartile ranges for non-normally distributed variables. 
Categorical data were presented as counts and percentages. Bayesian modelling was used to 
adjust seroprevalence estimates for the sensitivity and specificity of the assay. Non-
informative priors were used for all parameters, and the models were fitted using the Rstan 
software package15 (see appendix for code). We tested for associations between 
seroprevalence and professional cadre and site, respectively using multivariable logistic 
regression.  
All analyses were conducted using Stata™ Version 15 software (College Station, Texas, USA) 
and R version 3.6.1 (Vienna, Austria).  
RESULTS 
We recruited 684 HCWs from Nairobi, Busia and Kilifi (Figure S2 and Table 1). The numbers 
of the HCWs that we recruited as a proportion of total number of staff at the facilities were 

















± 11 years and 54% were female. Sixteen (2%) of the HCWs reported that they had acute 
respiratory symptoms at the time of sample collection. 
Out of the 684 HCWs, 135 (19.7%) were seropositive for antibodies to SARS-CoV-2 (Table 2). 
After adjusting for test performance characteristics, the seroprevalence was 20.8% (95% 
Credible Interval 17.5-24.4). Adjusted seroprevalence among the different cadres ranged 
from 12.5% (95% Cr I 5.4-21.8) among Clinical Officers to 34.2% (95% CrI 23.7-45.8) among 
doctors. There was a higher seroprevalence among HCWs in Nairobi (43.8%, 95% CrI 35.8-
52.2) compared with Kilifi (11.9%, 95% CrI 7.2-17.6) and Busia (12.6%, 95% CrI 8.8-17.1).  
Table 3 displays the results of univariable and multivariable logistic regression modeling 
testing associations between participant characteristics and seroprevalence. The only 
exposure variable that displayed a statistically significant association with seroprevalence in 
the multivariable model was site; HCWs in Kilifi (OR 0.2, 95% CI 0.1-0.3) and Busia (OR 0.2, 
95% CI 0.1-0.4) were less likely to be seropositive compared to those in Nairobi. Professional 
cadre, age and sex were not associated with seroprevalence in both univariable and 
multivariable analyses. Site-specific analyses also did not reveal any association between 
seroprevalence and professional cadre (Table S1). 
 
DISCUSSION 
We report results of a SARS-CoV-2 seroprevalence study conducted among HCWs in 3 
counties in Kenya. We found an overall seroprevalence of SARS-CoV-2 antibodies of 20.8% 
(95% CrI 17.5-24.4%). There were significant differences in seroprevalence associated with 
hospital region, but no differences associated with professional cadre. 
Our estimates of seroprevalence are higher than what was found in most of studies from 

















had a pooled seroprevalence of 8.2% (95% CI 0.8-22.3)17. We conducted our study during 
and shortly after the first wave of the epidemic in Kenya4, while the previous studies in 
Africa were conducted relatively early in the epidemic. Our estimates are similar to those 
observed among HCWs in several high-income countries at the peak of their first wave of 
the epidemic17.  
Consistent with other studies conducted in Kenya4, 14, 18-20, we found significant differences in 
seroprevalence by region. HCWs in urban Nairobi had significantly higher seroprevalence 
than those in Busia and Kilifi, which are rural counties. Studies in Spain and India have also 
shown significant regional differences, with higher seroprevalence in urban areas, such as 
Madrid and New Delhi, compared to rural areas21, 22. However, even in the rural counties in 
Kenya, HCWs had seroprevalence estimates that were similar to those in HCWs in urban 
areas in Spain23, USA24 and Malawi6.  
We found no differences in seroprevalence by professional category even when the analyses 
were stratified by study site. The absence of differences in seroprevalence by cadre in the 
presence of significant differences by geographical region suggests that community 
transmission could be playing a bigger role than workplace exposure. In studies of HCWs 
conducted in the UK, the incidence of infection mirrored that seen in the community2, 25. 
This suggests that efforts to suppress community transmission are likely to reduce infections 
among HCWs.  
The results of this study provide further evidence that there has been significant 
undocumented transmission of the SARS-CoV-2 virus within Kenya. Additional evidence of 
significant undocumented transmission in Kenya derives from (1) two studies of 
seroprevalence among blood transfusion donors14, 18; (2) a study of truck drivers and their 
assistants conducted at the same time as this survey in Kilifi and Busia that found a 

















was 50% at Kenyatta National Hospital in August 2020, and 11% at Kilifi County Hospital in 
November 202020.  
A particular strength of this study is that we conducted it in several sites, which enabled us 
to detect a significant burden of infection among HCWs in rural parts of the country. 
Another strength is that we used an assay that was validated using both local and external 
samples and which performed well in a WHO-sponsored international standardization 
study26. Although we adjusted our figures using Bayesian modelling to take into account 
assay performance, the reported seroprevalence could still be underestimated due to 
antibody waning27. The longitudinal phase of the current study will help address this issue. 
Another possible reason for underestimation of the prevalence in our study would be 
spectrum bias28 since the samples that we used in validating the assay, although derived 
from the local population, these individuals were not necessarily the same as the HCWs that 
participated in the present survey.  
Our study had several limitations. We did not perform genetic sequencing to establish the 
likely sources of infections among the HCWs, although as argued above, the data we 
obtained suggests that community transmission was the main driver of infections among the 
HCWs. The non-random selection of only a small proportion of the HCWs in Nairobi could 
have led to an overestimation of the seroprevalence if the HCWs sampled had an 
overrepresentation of individuals who had experienced symptoms in the past. However, this 
would have also resulted in a higher proportion of HCWs in Nairobi having positive results 
from previously conducted PCR tests, but we did not observe this. In addition a household 
survey found that 35% of the population in Nairobi had antibodies to SARS-CoV-229, and the 
rural-urban difference in seroprevalence among HCWs that we observed was similar to what 

















In conclusion, we found a high prevalence of antibodies to SARS-CoV-2 among HCWs in 
Kenya, with significant regional differences and no differences based on cadre. The results 
suggest that infection with SARS-CoV-2 among HCWs is driven more by background 
population levels of infection than workplace exposure and will be useful in informing 
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Table 1: Characteristics of study participants  
















19 Oct-23 Oct 
N=301 
Characteristic  n (%)  n (%)  n (%)  n (%) 
Female  372 54  113 57  99 54  160 53 
Age group (years)
a
              
18-30  232 34  65 33  67 37  100 33 
31-40  226 33  69 35  54 30  103 34 
41-50  117 17  34 17  31 17  52 17 
51-60  85 13  20 10  20 11  45 15 
>60  17 3  8 4  9 5  0 0 
PCR swab previously collected  250 37  31 16  77 43  142 47 
Positive on previous swab  5 2  1 3  0 0  4 3 
Symptoms at sample 
collection 
 16 2  0 0  16 9  0 0 
Chronic illness
b
  18 3  0 0  18 10  0 0 
Work in Covid Unit
c
  50 7  0 0  0 0  50 16 
Cadre             
Nurse  152 22  42 21  50 27  60 20 
Doctor  85 12  21 11  53 29  11 4 
Clinical Officer  79 12  48 24  4 2  27 9 
Support staff
d
  117 17  33 17  21 11  75 25 
Pharmacy  19 3  4 2  7 4  8 3 
Laboratory  64 9  13 7  7 4  44 15 
e
Other  168 25  39 20  41 22  76 29 
a
Age missing for 7 individuals 
b
Chronic illness- hypertension, diabetes, asthma, HIV 
c
None of the HCWs in Nairobi and Kilifi worked in a Covid unit  
d
Support staff includes: kitchen staff, patient porters, security staff, records clerks 
e



















Table 2: Seroprevalence of antibodies to SARS-CoV-2 by participant characteristics 









      
18-30  232 49 21.1 22.1 (16.5-28.5) 
31-40  226 46 20.4 21.6 (15.8-27.8) 
41-50  117 20 17.1 
18.3 (11.6-26.7) 
51-60  85 15 17.7 18.8 (10.9-28.5) 
>60  17 4 23.5 27.9 (9.3-50.8) 
Sex  
      
Female  372 69 18.6 19.3 (15.1-24.1) 
Male  312 66 21.2 22.1 (17.2-27.7) 
Cadre       
  Nurse  152 29 19.1 20.2 (13.8-27.9) 
  Doctor  85 27 31.8 34.2 (23.7-45.8) 
  Clinical Officer  79 9 11.3 12.5 (5.4-21.8) 
  Support staff  117 25 21.3 22.9 (15.2-31.6) 
  Pharmacy  19 5 26.3 30.3 (11.3-51.9) 
  Laboratory  64 12 18.8 20.4 (10.6-31.5) 
  Other  168 28 16.7 17.5 (11.8-24.3) 
Site       
  Kilifi  200 23 11.5 11.9 (7.2-17.6) 
  Nairobi  183 75 41.0 43.8 (35.8-52.2) 
  Busia  301 37 12.3 12.6 (8.8-17.1) 
Total  684 135 19.7 20.8 (17.5-24.4) 


















Table 3: Univariable and multivariable analysis of factors associated with presence of antibodies to 
SARS-CoV-2 
 
Characteristic  Univariable  Multivariable
§
 
Sex  OR (95 % CI)  OR (95% CI) 
  Female  1.0 –  1.0 – 
  Male  1.18 (0.81-1.71)  1.13 (0.75-1.72) 
Age (per decade)  1.00 (0.98-1.01)  0.99 (0.98-1.01) 
Site       
   Nairobi  1.0 –  – – 
   Kilifi  0.19 (0.11-0.32)  0.18 (0.10-0.33) 
   Busia  0.20 (0.13-0.32)  0.21 (0.13-0.36) 
Working in Covid unit  0.33 (0.12-0.94)  0.51 (0.17-1.55) 
Symptoms at sample 
collection 
 1.98 (1.08-3.63)  1.34 (0.78-2.30) 
Chronic illness  2.49 (0.88-6.97)  0.91 (0.30-2.72) 
Cadre       
   Nurse  1.0 –  1.0 – 
   Doctor  1.97 (1.07-3.63)  1.20 (0.61-2.35) 
   Clinical Officer  0.55 (0.24-1.21)  0.97 (0.41-2.30) 
   Support staff  1.15 (0.63-2.09)  1.56 (0.80-3.07) 
   Pharmacy  1.51 (0.51-4.54)  1.50 (0.45-4.97) 
   Laboratory  0.98 (0.46-2.06)  1.45 (0.64-3.27) 
   Other  0.85 (0.48-1.50)  0.97 (0.53-1.81) 
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